5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

Seeking Alpha • 6 hours ago

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

The Vanguard Health Care ETF offers a significantly lower expense ratio and a higher dividend yield than the State Street SPDR S&P Pharmaceuticals ETF. The State Street SPDR S&P Pharmaceuticals ETF provides concentrated exposure to drug manufacturers, while the Vanguard Health Care ETF covers a broader range of medical services and equipment.

The Motley Fool • Sep 10, 2026

These 5 ETFs Are Built for Bear Markets. History Says Now Is a Fantastic Time to Buy.

To brace against market pullbacks, add some defensive stocks or funds to your mix. Defensive industries include healthcare, utilities, and consumer staples.

The Motley Fool • Sep 11, 2026

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios and strong R&D pipelines, are better positioned to offset looming patent cliffs.

Seeking Alpha • Sep 8, 2026

Vanguard Health Care ETF vs Simplify Health Care ETF

Vanguard Health Care ETF provides broad, low-cost exposure to over 400 stocks with a significantly lower expense ratio than Simplify Health Care ETF. Simplify Health Care ETF is an actively managed, pro bono fund that has delivered higher 1-year total returns despite a higher expense ratio.

The Motley Fool • Sep 1, 2026

Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs

Nine of the 16 Big Pharma stocks covered in this article set new 52-week highs during August, reflecting strong momentum across the sector. Also, the rally has been driven by strong Q2 results, as well as Wall Street's growing shift toward healthcare amid continued geopolitical tensions in the Middle East.

Seeking Alpha • Aug 31, 2026

Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Vanguard Health Care Index Fund ETF Shares (VHT) is a passively managed exchange traded fund launched on January 26, 2004.

Zacks Investment Research • Aug 18, 2026

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

Vanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF. State Street Health Care Select Sector SPDR ETF is slightly more cost-effective with an expense ratio of 0.08% versus 0.09% for the Vanguard fund.

The Motley Fool • Aug 8, 2026

Health Care Shakes Off A 5-Day Slide

Health Care ended a five-day losing streak on Wednesday with a 1.34% rally. The streak tied the five days ending June 18 for the sector's longest of 2026.

Seeking Alpha • Aug 7, 2026

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broader health care exposure and has a a lower expense ratio than the Invesco Biotechnology & Genome ETF (PBE). PBE has delivered a stronger 1-year return, but has also experienced a much steeper 5-year maximum drawdown.

The Motley Fool • Jul 30, 2026